Previous studies have shown that neoadjuvant chemotherapy increased the CSC subpopulation  and that EZH2 promotes
the expansion of CSCs [11,20]. It is possible then that the expression of EZH2 described in this cohort is influenced by neoadjuvant chemotherapy. This should be considered in future studies. Conclusion In conclusion, this retrospective study showed that EZH2 is associated with receptor-negative status and lower locoregional-recurrence free survival rates in IBC patients. Additional examination of the PI3K inhibitor mechanism of this clinical finding and its association with triple negative receptor status is warranted. These findings indicate that EZH2 expression status may be used in conjunction with ER + status to identify a subset of patients with IBC who recur locally in spite of radiation and may benefit from enrollment in clinical trials testing radiosensitizers. Given the high frequency of expression of EZH2 and local recurrence in IBC patients, targeting EZH2 may provide a novel Poziotinib nmr therapeutic strategy to improve local
failure of patients with IBC. Acknowledgements This work was supported by the State of Texas Grant for Rare and Aggressive Breast Cancer Research Program, the National Institutes of Health R01CA138239-01 and Susan G. Komen Postdoctoral Fellowship Award (KG101478). References 1. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz
TA: Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 2011, 16(12):1675–1683.PubMedCentralPubMedCrossRef 2. Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA: Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 2011, 18(10):2851–2857.PubMedCrossRef 3. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM: WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor Janus kinase (JAK) cells. Proc Natl Acad Sci U S A 2007, 104(2):618–623.PubMedCentralPubMedCrossRef 4. Phillips TM, McBride WH, Pajonk F: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24):1777–1785.PubMedCrossRef 5. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA: Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 2010, 76(3):889–895.PubMedCentralPubMedCrossRef 6.